Compound 943
Identifiers
- Canonical SMILES: 
CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1N(=O)=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(CC1)C(c1ccc(F)cc1)c1ccc(F)cc1
 - IUPAC name: 
4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-N-[4-[[(2S)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide
 - InChi: 
InChI=1S/C42H44F2N6O5S2/c1-47(2)23-22-35(29-56-37-6-4-3-5-7-37)45-39-21-20-38(28-40(39)50(52)53)57(54,55)46-42(51)32-12-18-36(19-13-32)48-24-26-49(27-25-48)41(30-8-14-33(43)15-9-30)31-10-16-34(44)17-11-31/h3-21,28,35,41,45H,22-27,29H2,1-2H3,(H,46,51)/t35-/m1/s1
 - InChiKey: 
NVFSUIUMDIMAMA-PGUFJCEWSA-N
 
External links
        
        ![]() 68854914  | 
      
External search
         
       | 
      
         
       | 
      
           
       | 
      
           
       | 
      
           
       | 
    
Bibliography (1)
| Publication | Name | 
|---|---|
| Haixiao Zhai, Xiong Cai, Curis, Inc.. . Bcl-2 inhibitors None. | 2 | 
Pharmacological data
| Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests | 
|---|---|---|---|
| 1 | 0 | 0 | 0 | 
Targets
| PPI family | Best activity | Diseases | MMoA | 
|---|---|---|---|
| BCL2-Like / BAX | 5.30 | cancer | Inhibition | 
Physicochemical filters
| Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
|---|---|---|---|---|
| Compliance | ||||
| MW | 814.28 g/mol | |||
| HBA | 11 | |||
| HBD | 2 | |||
| HBA + HBD | 13 | |||
| AlogP | 7.20 | |||
| TPSA | 130.81 | |||
| RB | 15 | 
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
| Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests | 
|---|---|---|---|---|
| 1 | 1 | 0 | 0 | 0 | 
Pharmacological data
| Bibliography | Name | Target | Competition | Assay type | Assay name | Cell line | Activity type | Activity | 
|---|---|---|---|---|---|---|---|---|
| WO2009036035 | 2 | BCL2  P10415  | 
                      | 
                    Biochemical assay | Fluorescence Polarization | pIC50 (half maximal inhibitory concentration, -log10) | 5.30 | 
| Ta | Structure | Name | Drugbank ID | 
|---|---|---|---|
| 0.5479 | Navitoclax | DB12340 | |
| 0.4628 | Venetoclax | DB11581 | |
| 0.4227 | (2R)-1-[(4-tert-butylphenyl)sulfonyl]-2-methyl-4-(4-nitrophenyl)piperazine | DB07049 | |
| 0.4220 | Sulfabenzamide | DB09355 | |
| 0.3990 | 3-Nitro-4-(2-Oxo-Pyrrolidin-1-Yl)-Benzenesulfonamide | DB04394 | |
| 0.3974 | SC-74020 | DB01630 | |
| 0.3934 | Bitopertin | DB12426 | |
| 0.3930 | 2-({[3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)phenyl]carbonyl}amino)benzoic acid | DB07691 | |
| 0.3911 | ABT-639 | DB15055 | |
| 0.3909 | [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID | DB07986 | |
| 0.3889 | HSD-016 | DB12419 | |
| 0.3849 | Zafirlukast | DB00549 | |
| 0.3790 | Amisulpride | DB06288 | |
| 0.3750 | KD3010 | DB05188 | |
| 0.3740 | Repinotan | DB06506 | 




